Fig. 2From: Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting systemEndocrine toxicity profiles for different ICI combination therapy strategies*. *In Fig. 2, PT: preferred term; IC: information component; IC025: the lower end of the 95% confidence interval of IC. IC025 greater than 0 was deemed a signalBack to article page